Correction to: Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation

AAPS PharmSciTech. 2020 May 19;21(5):144. doi: 10.1208/s12249-020-01703-2.

Authors

Emine Tashan^{1

2}, Alptug Karakucuk¹, Nevin Celebi³

Affiliations

¹ Department of Pharmaceutical Technology, Faculty of Pharmacy Gazi University, Ankara, Turkey.
² Zoleant Pharmaceuticals International, Istanbul, Turkey.
³ Department of Pharmaceutical Technology, Faculty of Pharmacy Gazi University, Ankara, Turkey. [email protected].

PMID: 32430673
DOI: 10.1208/s12249-020-01703-2

Abstract

Several typos occurred during the production process and captions were misplaced. The corrected captions for Picture 1, Fig. 6-9 are below.

Publication types

Published Erratum